Additional factor X enhances emicizumab-driven coagulation function in patients with hemophilia A and hemophilia A mice

Background: Bypassing agents are used for breakthrough bleedings in patients with hemophilia A with inhibitor (PwHAwI) receiving emicizumab prophylaxis. Previous study demonstrated a weak binding affinity between emicizumab and factor (F)X (Kd; 1.85 μM), and that this value was much greater than the plasma FX concentration (~130 nM). We speculated that increased FX levels could enhance coagulation potential in emicizumab-treated PwHA. Aims: To investigate the relationship between FX concentrations and emicizumab-driven coagulation. Methods: Plasma FX (up to 1,040 nM) and emicizumab (50 µg/mL) were added to FVIII-deficient plasmas, and plasma-derived FX (520 nM) or recombinant (r)FVIIa (2.2 µg/mL) was added to plasmas from three emicizumab-treated PwHAwI. The adjusted-maximum coagulation velocity (Ad|min1|) by clot waveform analysis and peak thrombin (PeakTh) by thrombin generation assay in them were evaluated. Emicizumab (3.0 mg/kg), human (h)FIX (100 IU/kg), and various doses of hFX (100-500 IU/kg) were intravenously administered to HA mice. Clotting time/clot formation time (CT/CFT) were assessed using rotational thromboelastometry, and blood loss was estimated by a tail-clip assay. Results: The addition of FX to FVIII-deficient plasma with emicizumab increased Ad|min1| and PeakTh. The coagulation parameters in emicizumab-treated PwHAwI spiked with additional FX remained within the normal range as well as the additional rFVIIa. In animal models, hFX injection shortened the CT and CT+CFT. The shorter CT and CT+CFT, and the lower blood loss were evident after 200 or 500 IU/kg hFX administration, and those indices were comparable to those in wild-type mice. Conclusion: Supplementation with FX may improve emicizumab-driven hemostasis in PwHA.

Publication History

Received: 06 December 2023

Accepted after revision: 25 April 2024

Accepted Manuscript online:
27 April 2024